Tirzepatide 30mg Synbio Pen | Research Peptide | EU Manufactured

Tirzepatide (LY3298176 / P1206) is a first-in-class synthetic dual incretin peptide agonist that simultaneously activates two key metabolic receptors: GLP-1R (glucagon-like peptide-1 receptor) and GIPR (glucose-dependent insulinotropic polypeptide receptor). Its unimolecular dual-agonist architecture, combined with a C20 fatty acid side-chain modification for enhanced stability and albumin binding, makes it one of the most widely referenced incretin-based compounds in current metabolic research literature.

The Synbio Pen format (30mg) is designed for extended research protocols and dose-escalation workflows, offering a pre-loaded, ready-to-use delivery format that minimises preparation variables and reduces contamination risk in controlled laboratory environments.

Research Applications Investigators are currently studying Tirzepatide across multiple areas, including:

• Dual incretin receptor signalling and GIP/GLP-1 receptor cross-talk
• Glucose homeostasis, insulin secretion, and glucagon suppression
• Obesity and body composition research models
• NAFLD/NASH hepatic lipid clearance endpoint studies
• Visceral vs. subcutaneous adipose tissue differentiation
• Cardiometabolic and lipid metabolism investigation

Quality & Sourcing Manufactured within the EU under controlled synthesis conditions. Each batch is HPLC-verified to ≥99% purity and supported by a full Certificate of Analysis (COA) covering compound identity, purity, and batch traceability. Tamper-evident packaging is compatible with laboratory intake and SOPs.

Storage: Refrigerate at 2–8 °C. Do not freeze. Stable at room temperature during transit for up to 30 days.

For Research Use Only. Not for human or animal consumption. Not approved for therapeutic, diagnostic, or veterinary use. By purchasing, the buyer confirms use is restricted to qualified professionals in lawful scientific research contexts.